Is AGENUS INC (AGEN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 88.7% / 30% | 37.8% / 30% | 0.4% / 30% | 9.46% / 5% | ✗ NOT HALAL |
| DJIM | 88.7% / 33% | 37.8% / 33% | 0.4% / 33% | 9.46% / 5% | ✗ NOT HALAL |
| MSCI | 41.9% / 33% | 17.9% / 33% | 0.2% / 33% | 9.46% / 5% | ✗ NOT HALAL |
| S&P | 88.7% / 33% | 37.8% / 33% | 0.4% / 33% | 9.46% / 5% | ✗ NOT HALAL |
| FTSE | 41.9% / 33% | 17.9% / 33% | 0.2% / 50% | 9.46% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 96.5% | |
| Operating Margin | 42.1% | |
| Net Margin | 0.1% | |
| Return on Assets (ROA) | -5.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$77M |
| Free Cash Flow | -$77M |
| Total Debt | $56M |
| Current Ratio | 0.4 |
| Total Assets | $227M |
Price & Trading
| Last Close | $3.44 |
| 50-Day MA | $3.22 |
| 200-Day MA | $4.17 |
| Avg Volume | 649K |
| Beta | 1.7 |
|
52-Week Range
$1.38
| |
About AGENUS INC (AGEN)
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AGENUS INC (AGEN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AGENUS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AGENUS INC's debt ratio?
AGENUS INC's debt ratio is 88.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 41.9%.
What are AGENUS INC's key financial metrics?
AGENUS INC has a market capitalization of $130M, trailing P/E ratio of inf, and revenue of $114M. The company maintains a gross margin of 96.5% and a net margin of 0.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.